Citadel Advisors’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-13,700
| Closed | -$526K | – | 15543 |
|
|
2023
Q2 | $526K | Buy |
13,700
+9,200
| +204% | +$236K | ﹤0.01% | 7831 |
|
|
2023
Q1 | $104K | Sell |
4,500
-1,700
| -27% | -$40.5K | ﹤0.01% | 11200 |
|
|
2022
Q4 | $162K | Sell |
6,200
-254,000
| -98% | -$5.63M | ﹤0.01% | 10486 |
|
|
2022
Q3 | $5.12M | Sell |
260,200
-45,700
| -15% | -$917K | ﹤0.01% | 3819 |
|
|
2022
Q2 | $5.35M | Buy |
305,900
+272,500
| +816% | +$4.28M | ﹤0.01% | 3675 |
|
|
2022
Q1 | $546K | Buy |
+33,400
| New | +$454K | ﹤0.01% | 9176 |
|
|
2021
Q1 | – | Sell |
-13,400
| Closed | -$213K | – | 13886 |
|
|
2020
Q4 | $213K | Buy |
13,400
+11,020
| +463% | +$166K | ﹤0.01% | 9648 |
|
|
2020
Q3 | $29K | Buy |
+2,380
| New | +$31.9K | ﹤0.01% | 9778 |
|
|
2018
Q4 | – | Sell |
-2,940
| Closed | -$108K | – | 9949 |
|
|
2018
Q3 | $108K | Buy |
+2,940
| New | +$94.4K | ﹤0.01% | 8544 |
|
|
2017
Q2 | – | Sell |
-2,440
| Closed | -$131K | – | 8239 |
|
|
2017
Q1 | $131K | Buy |
+2,440
| New | +$138K | ﹤0.01% | 6753 |
|
|
2015
Q3 | – | Sell |
-160
| Closed | -$24K | – | 9330 |
|
|
2015
Q2 | $24K | Buy |
+160
| New | +$26.4K | ﹤0.01% | 8068 |
|
Citadel Advisors's KDNY Position: Q3 2023 in Review
Citadel Advisors sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 86,464 shares — an estimated $3.32M sold.
Citadel Advisors first reported a position in KDNY in Q2 2015 and held it in 24 quarters. The position peaked at $13.4M in Q4 2022. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Citadel Advisors reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Citadel Advisors sold 86,464 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $3.32M.
- Citadel Advisors first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 24 quarters.
- Citadel Advisors's Chinook Therapeutics, Inc. Common Stock position peaked at $13.4M in Q4 2022.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.